Join to View Full Profile
11100 Euclid AvenueCleveland, OH 44106
Dr. Jang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2023 - 2025
- Tulane UniversityChief Residency, Internal Medicine, 2022 - 2023
- Tulane UniversityResidency, Internal Medicine, 2019 - 2022
- Baylor College of MedicineClass of 2019, MD
- Rice UniversityBS, Biochemistry and Cell Biology, 2011 - 2014
Certifications & Licensure
- MN State Medical License 2025 - 2026
- OH State Medical License 2023 - 2026
- LA State Medical License 2022 - 2024
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Combining EPI-7386 with Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer Start of enrollment: 2024 May 16
Publications & Presentations
PubMed
- Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances.Albert Jang, Jason R Brown
Exploration of Targeted Anti-Tumor Therapy. 2025-01-01 - 1 citationsBlood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.Reagan M Barnett, Albert Jang, Sree Lanka, PIngfu Fu, Leslie A Bucheit
Communications Medicine. 2024-12-02 - 2 citationsImpact of Sodium-glucose cotransporter-2 inhibitors on Cardiovascular Outcomes of Prostate Cancer Patients Receiving Gonadotropin-Releasing Hormone Agonists.Zhiting Tang, Yu-Cheng Chang, Kuan-Yu Chi, Yu Chang, Tsae-Ni Lee
European Journal of Preventive Cardiology. 2024-08-17
Journal Articles
- Inferior Survival Among Polycythemia Vera Patients Exhibiting Body Mass Index Reduction.Albert Jang, Hussein Hamad, Sravanti Teegarapavu, Sarvari V. Yellapragada, Gustavo A. Rivero, SN Comprehensive Clinical Medicine, 4/10/2023
- PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic ReviewAlbert Jang, Patrick L. Sweeney, Pedro C. Barata, Vadim S. Koshkin, Kidney Cancer, 3/23/2021
- Systemic Lupus Erythematosus with Autoimmune Myelofibrosis, Immune Thrombocytopenic Purpura, and Widespread Lytic Bone Lesions Successfully Treated with Rituximab and ...Tejasvi K. Dasari, Jake Jacob, Annie Dai, Albert Jang, Lee Bach Lu, SN Comprehensive Clinical Medicine, 1/22/2021
- Join now to see all
Abstracts/Posters
- Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma with Pembrolizumab-based Induction Regimen Followed by Consolidative Radical Resecti...Albert Jang, Tanya Jindal, Adam C. Calaway, Jonathan E. Shoag, Vadim S. Koshkin, Pedro C. Barata, NCCN Conference, Orlando, FL, 4/6/2024
- Clinicogenomic characterization of patients with rapid tumor progression versus sustained response to frontline systemic therapy for metastatic urothelial carcinoma (mUC)Albert Jang, Sulin Wu, Hamsa Latha Sampath Kumar, Ravi Kumar Kyasaram, Chen-Han Wilfred Wu, Laura Bukavina, Adam C Calaway, Jorge A Garcia, Pedro C Barata, Prateek Men..., ASCO GU 24, San Francisco, CA, 1/25/2024
- Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.Reagan Barnett, Sree M Lanka, Keelia M Clemens, Lesli Ann Kiedrowski, Hani M Babiker, Alan Haruo Bryce, Haley M Meyer, Yujin Choi, Rohan Garje, Xin Gao, Richard Y Chan..., ASCO, Chicago, IL, 6/1/2023
- Join now to see all
Authored Content
- All in for the PatientJune 2020
- Promote a culture of medical school peer educationJune 2019
Press Mentions
- ASCO GU 2023: Comparison of ctDNA Between African American and Caucasian Patients with CRPC Post Abiraterone And/or EnzalutamideFebruary 16th, 2023
- AUA 2022: Prospective Evaluation of ctDNA in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary CancersJune 13th, 2022
- Alemtuzumab as Part of Conditioning Therapy for Graft-Vs-Host Disease in Children and Young AdultsJuly 24th, 2022
- Join now to see all
Other Languages
- Chinese (Mandarin), Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: